Market Cap (In USD)
328.06 Million
Revenue (In USD)
-
Net Income (In USD)
-381.64 Million
Avg. Volume
1.18 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 3.14-8.885
- PE
- -
- EPS
- -
- Beta Value
- 0.0
- ISIN
- US00445A1007
- CUSIP
- 00445A100
- CIK
- 1962918
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Mina Kim
- Employee Count
- -
- Website
- https://www.acelyrin.com
- Ipo Date
- 2023-05-04
- Details
- Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
More Stocks
-
000227Yuyu Pharma, Inc.
000227
-
ASGRPT Astra Graphia Tbk
ASGR
-
JAIPURKURTNandani Creation Limited
JAIPURKURT
-
002498Qingdao Hanhe Cable Co.,Ltd
002498
-
ECO-BEcoRub AB (publ)
ECO-B
-
051910LG Chem, Ltd.
051910
-
DUVNFPeruvian Metals Corp.
DUVNF
-
ASYL